Up and Coming

October 14, 2019

This feature highlights changes in clinical research organizations’ personnel.

AEON Biopharma

AEON Biopharma named Chris Carr chief financial officer. Carr was previously CFO and executive vice president of finance and IT at Dendreon Pharmaceuticals.

Aerie Pharmaceuticals

Charlene Davis has been named vice president and chief compliance officer at Aerie Pharamceuticals. Davis was previously head of healthcare compliance for North America at Sun Pharmaceutical Industries.

Aeterna Zentaris

Toronto-based Aeterna Zentaris has appointed Klaus Paulini president and chief executive officer and director. Paulini, based in Germany, was most recently managing director and vice president of quality and regulatory with Aeterna Zenartis.

Aidal Pharamaceuticals

Mark Peikin was named chief strategy officer of corporate communications at Aidal Pharmaceuticals. Previously, Peikin was chief executive officer of Bespoke Growth Partners.

Ascletis Pharma

Ascletis Pharma has named Handan He chief scientific officer. He was most recently global head of computational biopharmaceutics and translational PK/PD at Novartis.

Biodesix

Biodesix has appointed James Jett chief medical officer. Jett was most recently CMO with Oncimmune.

BioMarin Pharmaceutical

BioMarin has named Lon Cardon chief scientific strategy officer. Before joining BioMarin, Cardon served as senior vice president of alternative discovery and development and head of target sciences at GlaxoSmithKline.

Catalent

Guy Dewil has been appointed general manager of Catalent’s clinical supply facility in Germany. Dewil is the former vice president of global operations at Syneos Health.

Cerecin

Cerecin has appointed Lilian Chow vice president of clinical operations and regulatory affairs. Chow was most recently with ASLAN Pharmaceuticals where she was vice president of clinical operations, and research and development.

Cue Biopharma

Cue Biopharma has named Anish Suri as president. Suri was most recently chief science officer at Cue Biopharma and will remain in that role.

Cyclica

Vern De Biasi has been named vice president and global head of strategic partnerships with Cyclica. De Biasi most recently served as head of digital data and analytics for GlaxoSmithKline.

GenSight Biologics

Magali Taiel has been named chief medical officer at GenSight Biologics. Taiel was previously vice president of clinical development for GenSight Biologics.

Gilead Sciences

Gilead Sciences has added to its leadership with Merdad Parsey named chief medical officer. Parsey previously served as senior vice president of early clinical development in the Genentech Research and Early Development Group.

Grail

Matthew Young was named chief operating officer and chief financial officer at Grail. Previously, Young was executive vice president and CFO at Jazz Pharamceuticals.

Hepion Pharmaceuticals

Daren Ure has been appointed chief science officer, Daniel Trepanier has been named senior vice president of drug development and Patrick Mayo has been named senior vice president of clinical pharmacology at Hepion Pharmaceuticals. Ure was director of research and development, Trepanier was director of drug development and Mayo was director of clinical pharmacology at Ciclofilin Pharmaceuticals.

Johnson and Johnson

James Swanson has been appointed chief information officer at Johnson and Johnson. Swanson was previously CIO and head of digital transformation for crop science at Bayer and CIO at Monsanto.

MedeAnalytics

Scott Hampel was named president of MedeAnalytics. Previously, Hampel was chief product and strategy officer at the company.

OM1

OM1 has named Gary Curhan chief medical officer. Curhan is a practicing nephrologist in Boston, professor of medicine at Harvard Medical School, professor of epidemiology at Harvard’s School of Public Health and previously served as editor-in-chief for the Clinical Journal of The American Society of Nephrology.

Optinose

Optinose has named Michael Richardson the first vice president of business development. Richardson joined from Princeton BioPharma where he served as vice president of commercial operations.

Parexel

John Bell has been named executive vice president and chief quality officer at Parexel. Previously, Bell served as chief quality officer and senior vice president of corporate quality with Parexel.